CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of human GHRH with modifications to extend its half-life. The peptide stimulates growth hormone (GH) release from the pituitary gland in a pulsatile manner that mimics natural GH secretion. CJC-1295 exists in two forms: with and without Drug Affinity Complex (DAC). The DAC modification allows the peptide to bind to albumin in the bloodstream, dramatically extending its half-life from minutes to approximately 8 days. This makes CJC-1295 with DAC suitable for once-weekly administration while maintaining elevated GH and IGF-1 levels.
| Research Status | Clinical trials |
|---|---|
| Half-Life | 8 days (with DAC), 30 min (without DAC) |
| Administration | Subcutaneous injection |
| Typical Dosage | 100-200 mcg |
| Molecular Weight | 3,367.9 Da (without DAC) |
| Molecular Formula | C152H252N44O42 |
GHRH receptor agonist that stimulates pituitary to release GH in a pulsatile manner.
All information is presented for Research Use Only (RUO). Not medical advice.